Top Page
Therma Bright
(OTC:THRM)
Therma Bright (THRM) vs. iShares MSCI Canada ETF (EWC)
Therma Bright Business Overview & Revenue Model
Therma Bright Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 43.83K | 26.07K | 23.90K | 139.43K | 3.88K | 3.78K | Gross Profit |
| 36.36K | 25.46K | 23.90K | 63.48K | 3.88K | 3.78K | EBIT |
| -2.01M | -1.14M | -3.60M | -5.68M | -8.54M | -607.13K | EBITDA |
| -3.01M | -2.34M | -3.68M | -5.83M | -8.55M | -606.31K | Net Income Common Stockholders |
| -3.11M | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 35.62K | 1.10K | 182.24K | 3.08M | 1.78M | 1.06M | Total Assets |
| 3.09M | 3.19M | 2.21M | 4.00M | 2.24M | 1.15M | Total Debt |
| 50.72K | 65.39K | 90.39K | 110.55K | 40.00K | 95.94K | Net Debt |
| 48.38K | 64.30K | -91.85K | -2.97M | -1.74M | -965.83K | Total Liabilities |
| 1.85M | 1.87M | 2.16M | 1.25M | 927.12K | 924.32K | Stockholders Equity |
| 1.24M | 1.32M | 44.79K | 2.75M | 1.32M | 223.97K |
| Cash Flow | Free Cash Flow | ||||
| -1.00M | -1.01M | -2.44M | -3.80M | -3.16M | -104.94K | Operating Cash Flow |
| -1.00M | -1.01M | -2.17M | -3.80M | -2.86M | -104.94K | Investing Cash Flow |
| -138.26K | -138.26K | -691.08K | -204.93K | -300.00K | 0.00 | Financing Cash Flow |
| 1.14M | 966.40K | -33.60K | 5.31M | 3.87M | 1.14M |
Therma Bright Technical Analysis
Therma Bright Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | C$23.81M | ― | -23.87% | ― | 18.97% | 17.57% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
53 Neutral | C$6.82M | ― | -203.19% | ― | 69.93% | 20.54% | |
50 Neutral | C$21.51M | ― | -163.62% | ― | 113.85% | 11.38% | |
45 Neutral | C$46.40M | ― | -291.48% | ― | -8.63% | 7.04% | |
44 Neutral | C$18.79M | ― | 207.08% | ― | 280.56% | -7.28% | |
35 Underperform | $3.01M | ― | 1386.11% | ― | -100.00% | 60.42% |
Therma Bright Corporate Events
Therma Bright Inc. has announced a consolidation of its common shares, subject to TSX Venture Exchange approval, at a ratio of eight pre-Consolidation shares for one post-Consolidation share. This move is intended to provide the company with greater flexibility in structuring financings and business transactions, with no changes to its name or trading symbol expected.
Therma Bright Inc. has announced its intention to amend the exercise price of 42,725,000 outstanding common share purchase warrants, pending approval from the TSX Venture Exchange. The amendment aims to adjust the exercise price to $0.05 per share until December 31, 2025, and $0.10 per share thereafter until expiration in 2027. Additionally, Therma Bright has negotiated debt settlements with creditors, proposing to settle $124,000 in debt by issuing 6,200,000 common shares at $0.02 per share, subject to TSXV acceptance. These strategic financial adjustments could impact the company’s market positioning and stakeholder interests.
Therma Bright Inc. has announced significant progress in its InStatin project, which focuses on developing inhaled statin therapies for respiratory conditions. The company has appointed Professor Sir Peter Barnes, a renowned respiratory clinician, as a strategic advisor, and has completed a successful preclinical pharmacokinetic study. Additionally, Dr. Amir Zeki received a grant from the NIH for a statin efficacy study in monkeys. InStatin is also strengthening its intellectual property position with the help of an experienced IP attorney. These developments suggest a strategic entry into the asthma treatment market, potentially expediting regulatory approval compared to the COPD market.
Therma Bright Inc. has announced significant progress in its InStatin project, which focuses on developing inhaled statin therapies for respiratory conditions. The company has appointed Professor Sir Peter Barnes as a strategic advisor, completed a rodent pharmacokinetic study, and received a grant for a statin efficacy study in monkeys. These developments, along with efforts to strengthen their intellectual property, position InStatin to advance towards clinical trials and potentially address unmet needs in respiratory disease treatment.
Therma Bright Inc. has secured an initial purchase order for 200 units of its Venowave VW5 product from a key distributor in the Durable Medical Equipment sector, indicating strong market confidence in its offerings. This development highlights the potential for significant follow-on orders and expansion opportunities, as the company continues to navigate the global trade environment and manage debt settlements through share issuance.
Therma Bright Inc. is reviewing its manufacturing strategy for the Venowave device due to recent US tariff changes on goods from China, which could increase costs for products sold in the US. The company is considering onshoring manufacturing to North America or a hybrid approach to mitigate tariff impacts, while also evaluating factors such as supply chain resilience, lead times, and quality control. No final decision has been made yet, but Therma Bright is committed to keeping stakeholders informed as they navigate this evolving situation. Additionally, the company is working with national distributors to expand the market presence of Venowave, a compact, battery-operated device designed to enhance vascular and lymphatic flow in the lower limbs.
Therma Bright Inc. has secured an exclusive U.S. marketing and distribution contract with Global Wellness Products LLC for its consumer products, starting with the InterceptCS cold sore prevention device. This partnership aims to tap into the growing global cold sore treatment market, which was valued at USD 1.02 billion in 2024 and is projected to reach USD 1.57 billion by 2031, expanding Therma Bright’s market presence and product reach.